Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms POP
- Sponsors Biogen
- 28 Feb 2017 Planned End Date changed from 1 Aug 2022 to 1 Jan 2022.
- 28 Feb 2017 Planned primary completion date changed from 1 Aug 2022 to 1 Jan 2022.
- 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.